LILLY's PERMAX ACCEPTED AS ADJUNCT TO LEVODOPA

LILLY's PERMAX ACCEPTED AS ADJUNCT TO LEVODOPA in the treatment of Parkinson's disease by FDA's Peripheral and Central Nervous System Drugs Advisory Committee. In a unanimous decision at its May 19 meeting, the panel agreed that Lilly's multicenter Permax (pergolide mesylate) trial establishes safety and efficacy of the agent as adjunctive therapy for Parkinson's disease. The committee recommended approval based on a six-month, 16-center trial. Although FDA generally requires two independent clinical trials to support approval of a new drug, FDA Neuropharmacologic Drugs Division Director Paul Leber, MD, told the committee that in Permax's case, the agency decided that the single multicenter study is enough, because it provides "a persuasive body of evidence" and the results from the separate centers collaborate. Reporting results of the randomized, double-blind, placebo-controlled study, FDA medical review officer Jaenth Rouzer-Kammeyer, MD, stated that "in subjects experiencing a variable response to levodopa, pergolide administered in combination with levodopa demonstrates a levodopa clearing effect at the same time that it improves the overall Parkinson disability." The trial, which was initiated in September 1983, compared pergolide with placebo in 376 Parkinson's patients with idiopathic disease. Patients had to be of mild-to-moderate disability with less than optimal response to levodopa therapy. Patients received single daily doses of .05 mg pergolide or placebo for the first two days, and then the dose was gradually increased to .75 mg b.i.d. over the next 2 weeks, Rouzer-Kammeyer said. For the remainder of the study, the daily dosage could be titrated by .25 mg until an optimal dosage or a maximum dosage of 5 mg had been reached. "Sinemet dosage was to remain constant during the first two weeks of the study and then could be lowered during weeks 3 through 26," she noted. Sinemet's total daily dosage could not be increased during those weeks unless patients had received the maximum dose Permax for two weeks and were not sufficiently controlled, Rouzer-Kammeyer said. "Pergolide patients had a mean decrease in levodopa of 235 mg compared to 61 mg on placebo."

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

No Surprise Here: Foreign Drug Facilities Should Expect Surprise Inspections, US FDA Says

 
• By 

The FDA's recent announcement of plans to expand unannounced inspections at ex-US facilities should put firms on advance notice that their next foreign facility inspection may not be preannounced, Ivy Sweeney, acting head of the agency's drug inspections office said.

Base Benefit-Risk Decisions On Data, Not Opinion And Passion, CDER’s Tidmarsh Says

 
• By 

New US FDA drugs center director George Tidmarsh’s data-centric comments at a Reagan-Udall Foundation meeting on unapproved fluoride products could suggest patients’ and caregivers’ experiences will carry less weight in benefit-risk decisions under his leadership.

Pink Sheet Podcast: FDA’s New Top Drug Regulator, Sarepta’s Options After Elevidys Stand-Off

Pink Sheet reporter and editors discuss the potential impact George Tidmarsh could have as director of the US FDA Center for Drug Evaluation and Research and the issues threatening the future of Sarepta’s gene therapy Elevidys.